Actavis, which is being acquired by Watson Pharmaceuticals (WPI +0.2%), says that on June 29 it...
Actavis, which is being acquired by Watson Pharmaceuticals (WPI +0.2%), says that on June 29 it received tentative approval from the FDA for Guanfacine Extended-Release Tablets, a generic equivalent to Shire's (SHPGY -2.5%) Intuniv. Intuniv had US sales of approximately $342M for the 12 months ending March 31.
From other sites
Video at CNBC.com (Aug 6, 2015)
Video at CNBC.com (Jul 27, 2015)
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
at CNBC.com (Feb 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs